 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 1234» |
- | Imdelltra (tarlatamab-dlle) / Amgen
FDA event, Journal: 'Tarlatamab's FDA approval: shaping the future of cancer therapy'. (Pubmed Central) - Oct 3, 2024
No abstract available
- | Imdelltra (tarlatamab-dlle) / Amgen
Journal: Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report. (Pubmed Central) - Sep 23, 2024
Treatment was complicated by transient cytokine release syndrome but resulted in a partial response. Bispecific T cell engagers may offer a novel treatment approach for large cell neuroendocrine carcinoma of the lung.
- || Imdelltra (tarlatamab-dlle) / Amgen
Trial completion date, Trial primary completion date: DeLLphi-301: A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Sep 19, 2024
P2, N=222, Active, not recruiting, Sponsor: Amgen
Bispecific T cell engagers may offer a novel treatment approach for large cell neuroendocrine carcinoma of the lung. Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025
- Imdelltra (tarlatamab-dlle) / Amgen
Tarlatamab: a Bispecific T-cell Engager Immunotherapy Paving the Way for Small Cell Lung Cancer and Solid Tumors (George R. Brown Convention Center - Level 3 - Grand Ballroom B) - Sep 18, 2024 - Abstract #SITC2024SITC_50;
- | Imdelltra (tarlatamab-dlle) / Amgen
Journal: Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update. (Pubmed Central) - Sep 1, 2024
In modified Response Assessment in Neuro-Oncology Brain Metastases analyses, CNS tumor shrinkage of ?30% was observed in 62.5% of patients (10 of 16) who had a baseline CNS lesion of ?10 mm, including in a subset of patients with tumor shrinkage long after previous brain radiotherapy. In DeLLphi-300 extended follow-up, tarlatamab demonstrated unprecedented survival and potential findings of intracranial activity in previously treated SCLC.
- || Imdelltra (tarlatamab-dlle) / Amgen
Review, Journal: Tarlatamab: First Approval. (Pubmed Central) - Aug 23, 2024
Tarlatamab is under regulatory review in Brazil, Canada, Israel and the UK, and clinical studies are underway in multiple countries. This article summarizes the milestones in the development of tarlatamab leading to this first approval for ES-SCLC with disease progression on or after platinum-based chemotherapy.
- Imdelltra (tarlatamab-dlle) / Amgen
Tarlatamab with a PD-L1 Inhibitor as First-Line Maintenance after Chemo-immunotherapy for ES-SCLC: DeLLphi-303 Phase 1b Study (20A) - Aug 11, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2764;
P1, P3
No new or unexpected toxicities were identified. This study supports further investigation of tarlatamab in combination with a PD-L1 inhibitor as 1LM in the ongoing phase 3 DeLLphi-305 randomized controlled study (NCT06211036).
- Imdelltra (tarlatamab-dlle) / Amgen
DeLLphi-306 Trial: A Phase 3 Study of Tarlatamab after Concurrent Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer (Exhibit Hall) - Aug 4, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2696;
P3
Other secondary endpoints include investigator-assessed PFS, investigator and BICR-assessed objective response rate, disease control rate, duration of response, time to progression (all per RECIST 1.1), incidence of treatment-emergent and treatment-related adverse events, serum concentrations of tarlatamab, and incidence of anti-tarlatamab antibody formation. This trial is actively recruiting patients.
- Imdelltra (tarlatamab-dlle) / Amgen
DeLLphi-306 Trial: A Phase 3 Study of Tarlatamab after Concurrent Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1434;
P3
Other secondary endpoints include investigator-assessed PFS, investigator and BICR-assessed objective response rate, disease control rate, duration of response, time to progression (all per RECIST 1.1), incidence of treatment-emergent and treatment-related adverse events, serum concentrations of tarlatamab, and incidence of anti-tarlatamab antibody formation. This trial is actively recruiting patients.
- Imdelltra (tarlatamab-dlle) / Amgen, Imfinzi (durvalumab) / AstraZeneca
Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer: DeLLphi-305 Phase 3 Trial (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1430;
P3
Key exclusion criteria are prior DLL3 pathway-selective inhibitor therapy, active or documented autoimmune or inflammatory disorders per protocol, known human immunodeficiency virus, hepatitis C and/or hepatitis B infections with exceptions according to the protocol, and a history of severe/life-threatening events from immune-mediated therapy. The primary endpoint is OS and key secondary endpoints include progression-free survival, objective response rate, disease control rate, duration of response, safety, and quality of life assessments.
- Imdelltra (tarlatamab-dlle) / Amgen, Imfinzi (durvalumab) / AstraZeneca
Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer: DeLLphi-305 Phase 3 Trial (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1184;
P3
Key exclusion criteria are prior DLL3 pathway-selective inhibitor therapy, active or documented autoimmune or inflammatory disorders per protocol, known human immunodeficiency virus, hepatitis C and/or hepatitis B infections with exceptions according to the protocol, and a history of severe/life-threatening events from immune-mediated therapy. The primary endpoint is OS and key secondary endpoints include progression-free survival, objective response rate, disease control rate, duration of response, safety, and quality of life assessments.
- Imdelltra (tarlatamab-dlle) / Amgen
Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up (20A) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_924;
Tarlatamab showed a favorable benefit-risk profile, supporting tarlatamab use in patients with previously treated SCLC. The longer follow-up at time of presentation will provide clearer insight on response durability and long-term survival.
- | Imdelltra (tarlatamab-dlle) / Amgen
Journal: Tarlatamab (Imdelltra) for small cell lung cancer. (Pubmed Central) - Jul 9, 2024
The longer follow-up at time of presentation will provide clearer insight on response durability and long-term survival. No abstract available
- Imdelltra (tarlatamab-dlle) / Amgen
DLL3 Expression In Early () - Jun 23, 2024 - Abstract #LUNGSPORE2024LUNG_SPORE_86;
A trend for improved survival in patients with no DLL3 expression was observed. Future studies on DLL3 might improve SCLC treatment SCLC.
- |||||| Imdelltra (tarlatamab-dlle) / Amgen
Enrollment open, Combination therapy: DeLLphi-305: Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (clinicaltrials.gov) - Jun 21, 2024
P3, N=550, Recruiting, Sponsor: Amgen
Future studies on DLL3 might improve SCLC treatment SCLC. Not yet recruiting --> Recruiting
- | tarlatamab (AMG 757) / Amgen, Rova-T (rovalpituzumab tesirine) / AbbVie
Journal: DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy. (Pubmed Central) - May 11, 2024
Although rovalpituzumab tesirine (Rova-T) showed promise in a phase II study, it failed to produce favorable results in subsequent phase III trials, leading to the cessation of its development...Tarlatamab, for instance, demonstrated enhanced response rates and progression-free survival compared to the standard of care in a phase II trial; its biologics license application (BLA) is currently under US Food and Drug Administration (FDA) review...DLL3-targeted therapies hold substantial potential for SCLC management. Future clinical trials will be crucial for comparing treatment outcomes among various approaches and exploring combination therapies to improve patient survival outcomes.
- || Imdelltra (tarlatamab-dlle) / Amgen
Trial primary completion date, Combination therapy: DeLLphi-303: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov) - May 10, 2024
P1, N=340, Recruiting, Sponsor: Amgen
Future clinical trials will be crucial for comparing treatment outcomes among various approaches and exploring combination therapies to improve patient survival outcomes. Trial primary completion date: Dec 2025 --> Jan 2027
- Imdelltra (tarlatamab-dlle) / Amgen
DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC) (S406) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3262;
P2
Trial primary completion date: Dec 2025 --> Jan 2027 Tarlatamab showed promising efficacy and a favorable benefit-risk profile in patients with previously treated SCLC and stable brain metastases.
- Imdelltra (tarlatamab-dlle) / Amgen
Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). (Hall B1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2316;
P1
Findings from this phase 1 study of tarlatamab in pts with NEPC demonstrated manageable safety with encouraging anti-tumor activity in DLL3 expressing NEPC. Further investigation is ongoing.
- | Imdelltra (tarlatamab) / Amgen
Phase classification, Trial primary completion date: DeLLpro-300: A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer (clinicaltrials.gov) - Mar 25, 2024
P1, N=41, Active, not recruiting, Sponsor: Amgen
Further investigation is ongoing. Phase classification: P1b --> P1 | Trial primary completion date: Mar 2023 --> Aug 2025
- |||||| Imdelltra (tarlatamab-dlle) / Amgen
Enrollment open: DeLLphi-306: Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov) - Mar 11, 2024
P3, N=400, Recruiting, Sponsor: Amgen
Phase classification: P1b --> P1 | Trial primary completion date: Mar 2023 --> Aug 2025 Not yet recruiting --> Recruiting
- tarlatamab (AMG 757) / Amgen
Impact of patient specific factors on exposures of tarlatamab, a half-life extended DLL3-directed bispecific T-cell engager in patients with advanced small cell lung cancer (Section 24) - Mar 5, 2024 - Abstract #AACR2024AACR_9373;
P1, P2
Not yet recruiting --> Recruiting Overall, based on these analyses, no dose adjustment for tarlatamab is required based on age, sex, bodyweight, ethnicity, estimates of renal and hepatic function, prior lines of therapy, baseline disease status or emergence of ADA.
- tarlatamab (AMG 757) / Amgen
Exposure-efficacy and exposure-safety relationships of tarlatamab to inform dose selection and benefit-risk assessment in patients with advanced small cell lung cancer (SCLC) (Section 24) - Mar 5, 2024 - Abstract #AACR2024AACR_9370;
P1, P2
Overall results in this SCLC population suggest tarlatamab exposures associated with the recommended dose of 10 mg Q2W exhibited near maximal efficacy and a favorable benefit-risk profile. None of the evaluated patient-specific covariates resulted in clinically meaningful changes in efficacy or safety, and therefore do not warrant a dose adjustment.
- || Imdelltra (tarlatamab-dlle) / Amgen
Trial completion date, Trial primary completion date: DeLLphi-301: A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Mar 2, 2024
P2, N=222, Active, not recruiting, Sponsor: Amgen
None of the evaluated patient-specific covariates resulted in clinically meaningful changes in efficacy or safety, and therefore do not warrant a dose adjustment. Trial completion date: Feb 2025 --> Oct 2025 | Trial primary completion date: Feb 2024 --> Oct 2024
- ||||| Imdelltra (tarlatamab) / Amgen
Enrollment change, Trial primary completion date: DeLLphi-304: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (clinicaltrials.gov) - Feb 21, 2024
P3, N=490, Recruiting, Sponsor: Amgen
Trial completion date: Feb 2025 --> Oct 2025 | Trial primary completion date: Feb 2024 --> Oct 2024 N=700 --> 490 | Trial primary completion date: Sep 2025 --> Aug 2027
- |||| Imdelltra (tarlatamab-dlle) / Amgen
Trial primary completion date: DeLLphi-306: Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov) - Feb 15, 2024
P3, N=400, Not yet recruiting, Sponsor: Amgen
N=700 --> 490 | Trial primary completion date: Sep 2025 --> Aug 2027 Trial primary completion date: Jul 2028 --> Oct 2029
- tarlatamab (AMG 757) / Amgen
Tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC): DeLLphi-306 (NCT06117774) (Congress Hall Foyer) - Feb 6, 2024 - Abstract #ELCC2024ELCC_547;
P3
Primary endpoint is progression-free survival (PFS) per blinded independent central review (RECIST 1.1) with OS as a key secondary endpoint. Additional secondary endpoints include investigator-assessed PFS, objective response, disease control, duration of response, time to progression, pharmacokinetics, tarlatamab immunogenicity, and safety/tolerability.
- tarlatamab (AMG 757) / Amgen
Tarlatamab in previously treated small cell lung cancer (SCLC): DeLLphi-300 phase I study long-term outcomes and intracranial activity (Forum Hall) - Feb 6, 2024 - Abstract #ELCC2024ELCC_323;
P1
100 mg D1/D8 eIV, extended IV; NE, not estimable Conclusions In longer follow-up of DeLLphi-300, tarlatamab demonstrated durable responses and unprecedented survival outcomes in previously treated SCLC. While limited to analyses of treated, stable brain metastases, CNS tumor shrinkage following tarlatamab therapy and long after RT supports further study of intracranial efficacy of tarlatamab.
- | tarlatamab (AMG 757) / Amgen
Journal: Second-Line Treatment Options for Small-Cell Lung Cancer: A Light at the End of the Tunnel. (Pubmed Central) - Jan 23, 2024
Tarlatamab is a novel promising therapeutic antibody currently under investigation for its potential use in previously treated SCLC patients. This mini-review will explore the current state of second-line treatment options for SCLC, their clinical efficacy, and future directions.
- |||||||||| Imdelltra (tarlatamab-dlle) / Amgen
New P3 trial, Combination therapy: DeLLphi-305: Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (clinicaltrials.gov) - Jan 18, 2024
P3, N=550, Not yet recruiting, Sponsor: Amgen
- |||| Imdelltra (tarlatamab-dlle) / Amgen
Trial primary completion date: DeLLphi-306: Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov) - Jan 11, 2024
P3, N=400, Not yet recruiting, Sponsor: Amgen
This mini-review will explore the current state of second-line treatment options for SCLC, their clinical efficacy, and future directions. Trial primary completion date: Oct 2026 --> Jul 2028
- |||| Imdelltra (tarlatamab) / Amgen
Trial primary completion date: DeLLphi-304: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (clinicaltrials.gov) - Jan 3, 2024
P3, N=700, Recruiting, Sponsor: Amgen
Trial primary completion date: Oct 2026 --> Jul 2028 Trial primary completion date: Nov 2024 --> Sep 2025
- | Imdelltra (tarlatamab) / Amgen
Trial completion date: DeLLphi-300: Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Dec 21, 2023
P1, N=392, Recruiting, Sponsor: Amgen
Trial primary completion date: Nov 2024 --> Sep 2025 Trial completion date: Apr 2025 --> Oct 2025
- | tarlatamab (AMG 757) / Amgen
Journal: Tarlatamab Shows Promise in SCLC. (Pubmed Central) - Dec 17, 2023
Tarlatamab, an investigational bispecific T-cell engager molecule that targets the cell surface protein delta-like ligand 3, has shown promising activity in patients with small cell lung cancer whose disease had progressed after receiving another therapy. Questions remain over whether clinicians and patients would use the drug given its challenging administration.
- | Imdelltra (tarlatamab-dlle) / Amgen
Phase classification, Combination therapy: DeLLphi-303: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov) - Dec 8, 2023
P1, N=340, Recruiting, Sponsor: Amgen
Questions remain over whether clinicians and patients would use the drug given its challenging administration. Phase classification: P1b --> P1
- | tarlatamab (AMG 757) / Amgen
Clinical Trial,Phase II, Journal: Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. (Pubmed Central) - Dec 5, 2023
P2
No new safety signals were identified. (Funded by Amgen; DeLLphi-301 ClinicalTrials.gov number, NCT05060016.).
- tarlatamab (AMG 757) / Amgen
Tarlatamab in small cell lung cancer?safety and efficacy analyzed by baseline brain metastasis (8th Venue | Makuhari Messe International Conference Center 102) - Nov 16, 2023 - Abstract #JLCS2023JLCS_607;
- |||||||||| Imdelltra (tarlatamab-dlle) / Amgen
New P3 trial: DeLLphi-306: Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) (clinicaltrials.gov) - Nov 7, 2023
P3, N=400, Not yet recruiting, Sponsor: Amgen
- | Imdelltra (tarlatamab) / Amgen
Trial completion date: DeLLphi-300: Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Oct 26, 2023
P1, N=392, Recruiting, Sponsor: Amgen
(Funded by Amgen; DeLLphi-301 ClinicalTrials.gov number, NCT05060016.). Trial completion date: Oct 2025 --> Apr 2025
- || Imdelltra (tarlatamab-dlle) / Amgen
Trial completion date, Trial primary completion date, Combination therapy: DeLLphi-303: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov) - Oct 26, 2023
P1b, N=340, Recruiting, Sponsor: Amgen
Trial completion date: Oct 2025 --> Apr 2025 Trial completion date: Nov 2025 --> Jan 2027 | Trial primary completion date: Nov 2024 --> Dec 2025
- | Imdelltra (tarlatamab) / Amgen, zeluvalimab (AMG 404) / Amgen
Trial completion date, Combination therapy: AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Oct 11, 2023
P1b, N=23, Active, not recruiting, Sponsor: Amgen
Trial completion date: Nov 2025 --> Jan 2027 | Trial primary completion date: Nov 2024 --> Dec 2025 Trial completion date: Jan 2026 --> Jan 2025
- tarlatamab (AMG 757) / Amgen
Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study (Hall 406) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_394;
P2
Conclusions Tarlatamab demonstrated impressive antitumor activity with durable responses and promising survival. Tarlatamab showed a favorable benefit-risk profile with no new safety signals, supporting the use of tarlatamab in pts with previously treated SCLC.
- | Imdelltra (tarlatamab) / Amgen
Trial completion date: DeLLphi-300: Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Oct 5, 2023
P1, N=392, Recruiting, Sponsor: Amgen
Tarlatamab showed a favorable benefit-risk profile with no new safety signals, supporting the use of tarlatamab in pts with previously treated SCLC. Trial completion date: Mar 2025 --> Oct 2025
- | Imdelltra (tarlatamab-dlle) / Amgen
New P3 trial, Metastases: Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer (clinicaltrials.gov) - Oct 3, 2023
P3b, N=0, Available, Sponsor: Amgen
- |||| Imdelltra (tarlatamab) / Amgen
Trial completion date, Trial primary completion date: DeLLphi-304: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (clinicaltrials.gov) - Sep 28, 2023
P3, N=700, Recruiting, Sponsor: Amgen
Trial completion date: Mar 2025 --> Oct 2025 Trial completion date: May 2028 --> Sep 2027 | Trial primary completion date: Jul 2025 --> Nov 2024
- tarlatamab (AMG 757) / Amgen
Elucidating the effects of chemotherapy and immune checkpoint blockade on the activity of tarlatamab, a DLL3-targeting bispecific T cell engager molecule, in small cell lung cancer preclinical models (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1490;
The increased cytotoxic activity observed with the combination of tarlatamab and chemotherapy and/or anti-PD-L1 treatment suggests that tarlatamab may be used together with standard of care therapy to increase response rate or durability. These data support the continued clinical evaluation of tarlatamab in patients with SCLC, including in combination with chemo-immune therapy in the first-line setting.
- | Imdelltra (tarlatamab) / Amgen
Trial completion date: DeLLpro-300: A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer (clinicaltrials.gov) - Sep 22, 2023
P1b, N=41, Active, not recruiting, Sponsor: Amgen
These data support the continued clinical evaluation of tarlatamab in patients with SCLC, including in combination with chemo-immune therapy in the first-line setting. Trial completion date: May 2025 --> Aug 2025
- || tarlatamab (AMG 757) / Amgen, AMG 119 / Amgen, Rova-T (rovalpituzumab tesirine) / AbbVie
Review, Journal: Delta-like ligand 3 in small cell lung cancer: potential mechanism and treatment progress. (Pubmed Central) - Sep 16, 2023
However, other drugs that target DLL3, such as AMG119, AMG757 and DLL3-targeted NIR-PIT, bring new ideas for SCLC treatment. Overall, DLL3 remains a valuable target for SCLC.
- | tarlatamab (AMG 757) / Amgen
Journal: Tarlatamab: a potential new option for recurrent small cell lung cancer. (Pubmed Central) - Aug 14, 2023
Overall, DLL3 remains a valuable target for SCLC. No abstract available
- tarlatamab (AMG 757) / Amgen
Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study (Sevilla Auditorium - Hall 9) - Jul 27, 2023 - Abstract #ESMO2023ESMO_29;
P2
NE = not estimable Conclusions Tarlatamab demonstrated impressive antitumor activity with durable responses and promising survival. Tarlatamab showed a favorable benefit-risk profile with no new safety signals, supporting the use of tarlatamab in pts with previously treated SCLC.